找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Mesothelioma; From Research to Cli Giovanni Luca Ceresoli,Emilio Bombardieri,Maurizio Book 2019 Springer Nature Switzerland AG 2019 Lung tu

[復制鏈接]
樓主: 出租
21#
發(fā)表于 2025-3-25 05:43:20 | 只看該作者
22#
發(fā)表于 2025-3-25 09:57:16 | 只看該作者
23#
發(fā)表于 2025-3-25 13:26:47 | 只看該作者
24#
發(fā)表于 2025-3-25 17:43:35 | 只看該作者
Genetics and Epigenetics of Mesothelioma,ents. These patients are more sensitive to asbestos exposure than those who do not carry such mutations and may benefit of specific treatments. Additionally, epigenetic mechanisms, such as methylation or miRNA alterations, may modify gene expression and drive carcinogenesis. The same abnormalities m
25#
發(fā)表于 2025-3-25 22:23:44 | 只看該作者
26#
發(fā)表于 2025-3-26 02:49:07 | 只看該作者
Pathological Diagnosis of Mesothelioma, between benign and malignant mesothelial proliferations..This chapter is an update of the morphological, immunohistochemical, and molecular features, with particular regard to diffuse malignant mesothelioma diagnosis.
27#
發(fā)表于 2025-3-26 04:24:54 | 只看該作者
28#
發(fā)表于 2025-3-26 10:47:03 | 只看該作者
Role of Metabolic Imaging in Mesothelioma,characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by importan
29#
發(fā)表于 2025-3-26 15:49:12 | 只看該作者
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma,ideration..Individualization of care for each patient is mandatory in choosing the most appropriate treatment to minimize the complications and to maximize the benefits..The aim of this chapter is to give an overview on the current state of multimodality treatment in MPM.
30#
發(fā)表于 2025-3-26 20:34:11 | 只看該作者
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma,cond-line setting, if clinical trials are not available, single-agent therapy with vinorelbine or gemcitabine may be considered. Alternatively, patients achieving a prolonged benefit from first-line pemetrexed-platinum treatment may be candidate to rechallenge with pemetrexed-based regimens.
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 00:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
大石桥市| 城步| 琼海市| 建平县| 玉门市| 岑巩县| 舒兰市| 皋兰县| 体育| 普安县| 常宁市| 泗阳县| 商河县| 关岭| 崇州市| 泰宁县| 伊金霍洛旗| 田东县| 石家庄市| 天柱县| 大港区| 台山市| 陈巴尔虎旗| 龙门县| 于田县| 勐海县| 休宁县| 西安市| 耒阳市| 江西省| 兰州市| 合作市| 龙游县| 万州区| 台湾省| 应用必备| 宜昌市| 鄯善县| 黄山市| 长汀县| 开江县|